Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool

• Published in: Biomarker research Vol. 10; no. 1; p. 35
• Main Authors: Marañón, Patricia, Fernández-García, Carlos Ernesto, Isaza, Stephania C, Rey, Esther, Gallego-Durán, Rocío, Montero-Vallejo, Rocío, de Cía, Javier Rodríguez, Ampuero, Javier, Romero-Gómez, Manuel, García-Monzón, Carmelo, González-Rodríguez, Águeda
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.05.2022; BioMed Central; BMC
• Subjects: Algorithms; Apoptosis; Biopsy; BMP2; Bone morphogenetic protein 2; Bone morphogenetic proteins; Cell culture; Cholecystectomy; Fatty acids; Fatty liver; Gene expression; Hepatitis; Hepatocytes; Homeostasis; Hypertension; Inflammation; Insulin resistance; Laparoscopy; Liver diseases; Medical tests; Metabolism; Non-alcoholic fatty liver disease; Non-invasive diagnosis; Normal distribution; Palmitic acid; Proteins; Type 2 diabetes; Variables; Taiwan; Spain; United States > US; Madrid Spain; Germany; Bone morphogenetic proteins; BMP2; Non-invasive diagnosis; Hepatocytes; Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease worldwide, being non-alcoholic steatohepatitis (NASH) its most clinically relevant form. Given the risks associated with taking a liver biopsy, the design of accurate non-invasive methods to identify NASH patie...